Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 3:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination pill Clear all
Completed Phase 2 Interventional Results available

Cognitive Remediation for Cocaine Dependence

NCT01393457
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 3, 2026, 3:34 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Nov 3, 2026, 3:34 PM EST
Withdrawn Phase 2 Interventional

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

NCT01736800
View directory record Official record
Conditions
Central Nervous System (CNS) Metastases, Brain Metastases
Interventions
Topotecan, Temozolomide
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Results available

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

NCT04442737
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02007512
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

NCT04599478
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

NCT00700128
View directory record Official record
Conditions
Migraines, Bleeding, Spotting
Interventions
frovatriptan, placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Nov 3, 2026, 3:34 PM EST
Terminated Phase 2 Interventional Results available

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

NCT01205685
View directory record Official record
Conditions
Hormone-sensitive Metastatic Breast Cancer
Interventions
OSI-906, Erlotinib, Letrozole, Goserelin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Franklin, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment

NCT04188106
View directory record Official record
Conditions
Smoking Cessation, Stress, Sleep Disturbance, Nausea
Interventions
Varenicline Pill, Hydroxyzine Pill
Drug
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Nov 3, 2026, 3:34 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Pill (OCP) Pharmacogenomics

NCT06334315
View directory record Official record
Conditions
Contraception, Pharmacogenomic Drug Interaction
Interventions
Desogestrel / Ethinyl Estradiol Pill
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Terminated Phase 3 Interventional Results available

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

NCT00995722
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Michael Benatar
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 3 Interventional Results available

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

NCT00194129
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Divalproex, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Nov 3, 2026, 3:34 PM EST
Terminated Phase 2 Interventional Results available

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

NCT01004705
View directory record Official record
Conditions
Elevated LDL Cholesterol
Interventions
Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 3, 2026, 3:34 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

NCT03919435
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Nov 3, 2026, 3:34 PM EST
Terminated Phase 1 Interventional

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

NCT05679388
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions
Relugolix Pill, Ritonavir, Itraconazole
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 3:34 PM EST
Active, not recruiting Phase 2 Interventional

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

NCT05650723
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

NCT01109979
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Estradiol+MPA, Estradiol+Drospirenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Results available

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

NCT01360996
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3 mg DRSP/20 μg EE
Drug
Lead sponsor
Woman's
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cessation Screening Project

NCT04188873
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Preparation Varenicline and Standard Duration Varenicline, Preparation Varenicline and Extended Duration Varenicline, Standard Duration Varenicline, Extended Duration Varenicline, Preparation Combination NRT and Standard Duration Combination NRT, Preparation Combination NRT and Extended Duration Combination NRT, Standard Duration Combination NRT, Extended Duration Combination NRT, Intensive Counseling, Minimal Counseling
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional Results available

Health Systems Reach Interventions Project

NCT04199117
View directory record Official record
Conditions
Smoking, Cigarette, Smoking Cessation
Interventions
Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment, Automated tailored outreach, Care management, Wisconsin Tobacco Quit Line referral, Primary care provider referral, Untailored outreach, Multiple smoking cessation coaching calls
Drug · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 3, 2026, 3:34 PM EST
Completed Phase 4 Interventional

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT05743946
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Trikafta
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 3, 2026, 3:34 PM EST